Regulatory Directive: Shaanxi Sunrise operates strictly as a Business-to-Business (B2B) Active Pharmaceutical Ingredient (API) manufacturer. The technical data provided below is exclusively directed at Formulators, QA/QC Directors, R&D Scientists, and Procurement Managers. Our Desloratadine Powder (CAS No. 100643-71-8) is for R&D, laboratory, and commercial manufacturing scale-up use only. It is not a finished drug product and is strictly prohibited for direct human or animal consumption.

The global antihistamine manufacturing market is saturated with generic, poorly synthesized Desloratadine. Pharmaceutical formulators are currently battling skyrocketing failure rates during mandatory 6-month accelerated stability testing protocols. Vials of pediatric liquid syrups are inexplicably clouding on pharmacy shelves. Orally Disintegrating Tablets (ODTs) are failing their crucial dissolution profiles. These are not inherent formulation errors. They are fundamental API procurement failures originating from a broken supply chain.

Stop sourcing Desloratadine based solely on a generic ≥ 98% assay claim. A basic titration assay parameter cannot measure thermodynamic stability or predict behavior under high compression forces. If your active pharmaceutical ingredient broker does not understand polymorphic phase transitions, residual degradation catalysts, or excipient incompatibility, they are actively sabotaging your commercial drug pipeline. Purchasing cheap chemicals destroys millions in R&D investments. When you source CAS No. 100643-71-8 from Shaanxi Sunrise, you secure a highly engineered molecular matrix designed specifically to survive aggressive rotary tablet press compression and harsh excipient micro-environments. We deliver absolute analytical predictability.

Polymorphism is the silent killer of Desloratadine solid oral dosage forms. The Desloratadine molecule (C₁₉H₁₉ClN₂) exhibits multiple crystalline forms within its solid state, most notably Form I and Form II. Generic API manufacturers utilize uncontrolled, rapid cooling rates during their final solvent crystallization phase. This reckless approach results in a metastable polymorphic mixture that lacks thermodynamic permanence.

Here is the brutal reality of the commercial manufacturing floor: the extreme mechanical stress of your rotary tablet press, combined with trace residual moisture inside blister packaging, forces these metastable crystals to overcome their energy barriers. They slowly convert into a lower-energy, significantly lower-solubility polymorph over time. At month zero, your tablets pass Quality Control with flying colors. At month six under ICH conditions (40°C / 75% RH), your dissolution rate suddenly drops below the FDA Q-limit. The batch must be destroyed.

We eliminate this critical risk at the synthesis level. Our chemical engineers utilize highly controlled anti-solvent crystallization techniques, continuously monitored by in-line Raman spectroscopy. We mandate rigorous X-Ray Powder Diffraction (XRPD) and Differential Scanning Calorimetry (DSC) testing on every commercial batch to guarantee 100% phase-pure polymorphic stability. The exact crystal lattice you purchase from Shaanxi Sunrise is the exact crystal lattice that remains active in your tablet three years later. Zero shifting. Zero dissolution failures.

Desloratadine contains a highly reactive secondary amine group within its chemical structure. This makes it notoriously sensitive to its environment. If you formulate generic Desloratadine with common reducing sugars like Lactose, you immediately trigger a Maillard reaction, causing your bright white tablets to develop unacceptable brown discoloration.

Furthermore, trace amounts of formic acid present in common excipients (like Polyethylene Glycol or certain cellulosic binders) will react instantly with the API amine group to form N-formyl desloratadine. This is a critical degradation impurity heavily monitored by the EMA and FDA. You simply cannot formulate around a dirty API. Generic batches often contain elevated levels of residual transition metal catalysts and acidic byproducts that accelerate this oxidative degradation pathway.

Our proprietary purification process chemically strips out these degradation catalysts. We provide a highly stable, ultra-pure free-base Desloratadine with an impurity profile so deeply suppressed that it maximizes your excipient compatibility window. Your formulation R&D team finally gets the biochemical runway they need to develop stable ODTs and film-coated tablets without constantly fighting baseline API degradation.

Orally Disintegrating Tablets (ODTs) and pediatric suspensions require extreme physical and geometric precision. According to the Noyes-Whitney equation, dissolution velocity is directly proportional to the Specific Surface Area (SSA) of the drug particles. If your Desloratadine API is excessively coarse, two catastrophic things happen: pediatric patients reject the syrup due to an unpleasant gritty mouthfeel, and the API fails to dissolve rapidly in the limited saliva volume of the oral cavity.

However, you cannot simply dump generic Desloratadine powder into a standard jet mill. The intense friction heat generated by conventional micronization will trigger the exact polymorphic shift mentioned earlier, ruining the batch. We solve this through advanced engineering. We execute cryogenic micronization under a strictly controlled, inert nitrogen atmosphere. This chilling process protects the fragile crystal lattice from heat degradation while simultaneously achieving a hyper-tight Particle Size Distribution.

Utilizing wet-dispersion laser diffraction on a Malvern Mastersizer 3000, our QA team can customize the critical D10, D50, and D90 parameters strictly to your formulation requirements. Whether you need an ultra-fine profile for immediate suspension or a custom granular distribution, we ensure rapid disintegration, flawless suspension uniformity, and zero mouthfeel complaints.

Audit your raw material specifications rigorously. Shaanxi Sunrise sets a clinical-grade baseline that significantly exceeds generic pharmacopeial minimums to ensure seamless scale-up:

Ground your commercial formulation strategy in validated regulatory science and international compliance standards:

• FDA Database: Guidance for Industry: ANDAs: Impurities in Drug Substances.
  URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents

• EMA Regulatory Hub: ICH Q3A (R2) Impurities in New Drug Substances.
  URL: https://www.ema.europa.eu/en/ich-q3a

• NCBI Literature: Polymorphism and phase transitions of desloratadine.
  URL: https://pubmed.ncbi.nlm.nih.gov/

Yes. We supply comprehensive open-part DMF documentation in eCTD format. This includes the complete Route of Synthesis (RoS), detailed structural elucidation (NMR, IR, MS), impurity profiling against loratadine precursors, and over 36 months of real-time stability data covering both Zone II and Zone IVb climatic conditions.

The chemical conversion of loratadine to desloratadine often requires aggressive solvents like Toluene or Dichloromethane. Generic suppliers routinely fail to wash these completely from the crystal matrix. We deploy Gas Chromatography with Flame Ionization Detection (GC-FID Headspace) autosamplers to track Class 2 and Class 3 residual solvents down to the part-per-million. We ensure absolute compliance with ICH Q3C limits. Your manufacturing floor will never smell of solvent off-gassing when processing our material.

Desloratadine is highly sensitive to environmental humidity which can accelerate polymorphic shifting. We seal the API inside pharmaceutical-grade, double-layered antistatic Low-Density Polyethylene (LDPE) bags. These are vacuum-purged, nitrogen-flushed, hermetically sealed, and placed inside a medical-grade Tyvek pouch with precise, pre-calculated desiccant ratios. The entire unit is secured inside heavy-duty rigid fiber drums. The internal micro-climate remains perfectly stable regardless of external ocean freight conditions.

For commercial GMP batches (ranging from MOQ 10kg to 500kg), we execute priority out-bound staging protocols. Upon receiving your formal Purchase Order (PO), our QA batch release and export compliance documentation are systematically completed within 72 hours to facilitate immediate air-freight routing.

Absolutely. Unreacted Loratadine is a common residual impurity in poorly synthesized batches. Standard UV-Vis spectrophotometry cannot accurately differentiate the two molecules due to their nearly identical overlapping chromophores. We rely exclusively on high-resolution High-Performance Liquid Chromatography coupled with Mass Spectrometry (LC-MS) to validate the absolute absence of Loratadine precursors. This ensures your API assay reflects true, active Desloratadine content.

Stop Gambling With Your Antihistamine Formulations

Every failed dissolution test and every Out-of-Specification (OOS) stability result costs your pharmaceutical plant valuable time to market and massive financial losses. Do not let poorly synthesized generic APIs dictate your R&D success or risk your regulatory standing. Upgrade to a highly engineered, phase-stable active pharmaceutical ingredient. Cut out the middleman brokers who cannot mathematically explain a polymorphic shift.

Ready to stabilize your solid oral dosage forms and liquid suspensions? Contact the Shaanxi Sunrise technical engineering team today to demand our full analytical audit report and secure your clinical-grade Desloratadine API.